Released Mar 23, 2021, after the close
10-K filed Mar 23, 2021, 82 days after period end · 0001390478-21-000007
Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.90M$1.90M derivedno prior Q4 2019 on fileno prior Q3 2020 on file
Net Income-$3.72M-$3.72M derivedN/M vs Q4 2019N/M vs Q3 2020
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$4,159,000—
Operating Cash Flowderived$3,424,000N/M
Margins · derived
Operating margin-218.9%
Net margin-195.6%
What the release said
The release
Same quarter
| Metric | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures | Q4 2017dderived from reported figures |
|---|---|---|---|---|
| Revenue | $1.90M | — | — | — |
| Net Income | -$3.72M | -$7.42M | -$13.32M | -$8.79M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR